Find Regadenoson Monohydrate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 313348-27-5, Lexiscan, Rapiscan, Cvt-3146, Regadenoson anhydrous, 2-[4-[(methylamino)carbonyl]-1h-pyrazol-1-yl]adenosine
Molecular Formula
C15H18N8O5
Molecular Weight
390.35  g/mol
InChI Key
LZPZPHGJDAGEJZ-AKAIJSEGSA-N
FDA UNII
7AXV542LZ4

Regadenoson Monohydrate
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Regadenoson anhydrous is a Pharmacologic Cardiac Stress Test Agent. The mechanism of action of regadenoson anhydrous is as an Adenosine Receptor Agonist.
1 2D Structure

Regadenoson Monohydrate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide
2.1.2 InChI
InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1
2.1.3 InChI Key
LZPZPHGJDAGEJZ-AKAIJSEGSA-N
2.1.4 Canonical SMILES
CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N
2.1.5 Isomeric SMILES
CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
2.2 Other Identifiers
2.2.1 UNII
7AXV542LZ4
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Cvt 3146

2. Cvt-3146

3. Cvt3146

4. Lexiscan

2.3.2 Depositor-Supplied Synonyms

1. 313348-27-5

2. Lexiscan

3. Rapiscan

4. Cvt-3146

5. Regadenoson Anhydrous

6. 2-[4-[(methylamino)carbonyl]-1h-pyrazol-1-yl]adenosine

7. 7axv542lz4

8. Chembl317052

9. 1-(6-amino-9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9h-purin-2-yl)-n-methyl-1h-pyrazole-4-carboxamide

10. Adenosine, 2-[4-[(methylamino)carbonyl]-1h-pyrazol-1-yl]-

11. Regadenoson Monohydrate

12. Lexiscan (tn)

13. Cvt 3146

14. Regadenoson [usan:inn]

15. Unii-7axv542lz4

16. Adenosine, 2-(4-((methylamino)carbonyl)-1h-pyrazol-1-yl)-

17. Regadenoson [mi]

18. Regadenoson [inn]

19. Regadenoson (usan/inn)

20. Regadenoson; Cvt-3146

21. Dsstox_cid_31501

22. Dsstox_rid_97386

23. Regadenoson [mart.]

24. Dsstox_gsid_57712

25. Schembl678893

26. Gtpl5596

27. Dtxsid4057712

28. Chebi:135613

29. Hms3886o21

30. Amy27715

31. Ex-a2148

32. Hy-a0168

33. Tox21_113668

34. Bdbm50119132

35. S5358

36. Zinc13818943

37. Akos026750593

38. Ccg-268525

39. Cs-5612

40. Cv-3146

41. Db06213

42. 1-(6-amino-9-beta-d-ribofuranosyl-9h-purin-2-yl)-n-methyl-1h-pyrazole-4-carboxamide

43. Ncgc00249892-01

44. (1-(9-(3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl)pyrazol-4-yl)-n-methylcarboxamide

45. Ac-35838

46. As-56292

47. B5904

48. Cas-313348-27-5

49. Cvt-3146;cvt3146;cvt 3146

50. D05711

51. 348r275

52. J-018384

53. Q7307897

54. (1-{9-[(4s,2r,3r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-n-methylcarboxamide

55. 1-[6-amino-9-((2r,3r,4s,5r)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-9h-purin-2-yl]-1h-pyrazole-4-carboxylic Acid Methylamide

56. 1-{6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9h-purin-2-yl}-n-methyl-1h-pyrazole-4-carboxamide

57. 6-amino-2-[4-(methylcarbamoyl)-1h-pyrazol-1-yl]purine-9-yl-beta-d-ribofuranoside;1-(6-amino-9-((2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yloxy)-9h-purin-2-yl)-n-methyl-1h-pyrazole-4-carboxamide

2.4 Create Date
2005-08-09
3 Chemical and Physical Properties
Molecular Weight 390.35 g/mol
Molecular Formula C15H18N8O5
XLogP3-1.5
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count10
Rotatable Bond Count4
Exact Mass390.14001570 g/mol
Monoisotopic Mass390.14001570 g/mol
Topological Polar Surface Area187 Ų
Heavy Atom Count28
Formal Charge0
Complexity587
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameLexiscan
PubMed HealthRegadenoson (Injection)
Drug ClassesDiagnostic Agent, Cardiac Function
Drug LabelRegadenoson is an A2A adenosine receptor agonist that is a coronary vasodilator [see Clinical Pharmacology (12.1)]. Regadenoson is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-, monohydrate. Its structural formula...
Active IngredientRegadenoson
Dosage FormSolution
RouteIntravenous
Strength0.4mg/5ml (0.08mg/ml)
Market StatusPrescription
CompanyAstellas

2 of 2  
Drug NameLexiscan
PubMed HealthRegadenoson (Injection)
Drug ClassesDiagnostic Agent, Cardiac Function
Drug LabelRegadenoson is an A2A adenosine receptor agonist that is a coronary vasodilator [see Clinical Pharmacology (12.1)]. Regadenoson is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-, monohydrate. Its structural formula...
Active IngredientRegadenoson
Dosage FormSolution
RouteIntravenous
Strength0.4mg/5ml (0.08mg/ml)
Market StatusPrescription
CompanyAstellas

4.2 Drug Indication

Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)


FDA Label


This medicinal product is for diagnostic use only.

Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Regadenoson rapidly increases coronary blood flow (CBF) which is sustained for a short duration. Mean average peak velocity increased to greater than twice baseline by 30 seconds and decreased to less than twice the baseline level within 10 minutes. Myocardial uptake of the radiopharmaceutical is proportional to (CBF). Regadenoson increases blood flow in normal coronary arteries but not in stenotic (blocked) arteries. The significance of this finding is that stenotic arteries will take up less of the radiopharmaceutical than normal coronary arteries, resulting in a signal that is less intense in these areas.


5.2 MeSH Pharmacological Classification

Adenosine A2 Receptor Agonists

Compounds that selectively bind to and activate ADENOSINE A2 RECEPTORS. (See all compounds classified as Adenosine A2 Receptor Agonists.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
REGADENOSON ANHYDROUS
5.3.2 FDA UNII
7AXV542LZ4
5.3.3 Pharmacological Classes
Adenosine Receptor Agonists [MoA]; Pharmacologic Cardiac Stress Test Agent [EPC]; Adenosine Receptor Agonist [EPC]; Adenosine Receptor Agonists [MoA]
5.4 ATC Code

C01EB21


C01EB21

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


C - Cardiovascular system

C01 - Cardiac therapy

C01E - Other cardiac preparations

C01EB - Other cardiac preparations

C01EB21 - Regadenoson


5.5 Absorption, Distribution and Excretion

Absorption

The pharmacokinetic profile of regadenoson is best described by a 3-compartment model. T max, injection = 1 to 3 minutes; Onset of pharmacodynamic response = 1 to 3 minutes; E max 12.3 ng/mL


Route of Elimination

58% of total regadenoson eliminate is via renal excretion


Volume of Distribution

Central compartment: 11.5 L; Steady state: 78.7 L


Clearance

Average plasma renal clearance = 450 mL/min. As this value is larger than the glomerular filtration rate, this suggests occurrence of renal tubular secretion.


5.6 Metabolism/Metabolites

The metabolism of regadenoson is unknown in humans. The cytochrome P450 enzyme system is not likely to be involved with the metabolism of regadenoson.


5.7 Biological Half-Life

Initial phase: 2-4 minutes; Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect); Terminal phase: 2 hours


5.8 Mechanism of Action

Regadenoson is an selective low-affinity (Ki= 1.3 M) A2A receptor agonist that mimics the effects of adenosine in causing coronary vasodilatation and increasing myocardial blood flow. It is a very weak agonist of the A1 adenosine receptor (Ki > 16.5 M). Furthermore, it has negligible affinity to A2B and A3 adenosine receptors. Regadenoson is undergoing trials for use in pharmacological stress tests. Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.


USDMF

read-more
read-moreread-more

01

Farmak As

Czech Republic
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFarmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

Flag Czech Republic
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2021-02-18

Pay. Date : 2021-01-13

DMF Number : 35433

Submission : 2021-01-04

Status : Active

Type : II

Farmak Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2016-12-08

Pay. Date : 2016-09-16

DMF Number : 30834

Submission : 2016-09-13

Status : Active

Type : II

Biophore

03

Curia Missouri Inc

U.S.A

USDMF

arrow
Coatings Trends
Not Confirmed

03

Coatings Trends
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-05-24

Pay. Date : 2016-09-20

DMF Number : 30542

Submission : 2016-05-10

Status : Active

Type : II

blank

04

Gland Pharma Ltd

India

USDMF

arrow
Coatings Trends
Not Confirmed

04

Coatings Trends
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2014-05-15

Pay. Date : 2014-02-27

DMF Number : 27972

Submission : 2014-02-12

Status : Active

Type : II

blank

05

Coatings Trends
Not Confirmed

05

Coatings Trends
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 36338

Submission : 2021-11-26

Status : Active

Type : II

blank

06

Coatings Trends
Not Confirmed

06

Coatings Trends
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 36679

Submission : 2022-01-24

Status : Active

Type : II

blank

07

Scinopharm Taiwan Ltd

Taiwan

USDMF

arrow
Coatings Trends
Not Confirmed

07

Coatings Trends
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-10-16

Pay. Date : 2015-08-27

DMF Number : 28939

Submission : 2014-12-25

Status : Active

Type : II

blank

08

Coatings Trends
Not Confirmed

08

Coatings Trends
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2017-12-08

Pay. Date : 2017-03-27

DMF Number : 31539

Submission : 2017-11-24

Status : Active

Type : II

blank

09

Usv Private Ltd

India

USDMF

arrow
Coatings Trends
Not Confirmed

09

Coatings Trends
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-08-24

Pay. Date : 2015-06-24

DMF Number : 29315

Submission : 2015-06-23

Status : Active

Type : II

blank

10

Coatings Trends
Not Confirmed

10

Coatings Trends
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-12-04

Pay. Date : 2018-09-14

DMF Number : 32339

Submission : 2018-01-07

Status : Active

Type : II

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Regadenoson IH

Date of Issue : 2022-04-08

Valid Till : 2025-04-03

Written Confirmation Number : WC-0427

Address of the Firm : Plot No.49 & 50, J.N. Pharma City, Parawada (M), Visakhapatanam

blank

02

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Regadenoson IH

Date of Issue : 2023-11-15

Valid Till : 2026-05-11

Written Confirmation Number : WC-0273

Address of the Firm : Plot No: 34A, Road No: 1, Jawaharlal Nehru Pharma City, Thanam Village, Parawada...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

FARMAK, a.s

Czech Republic
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothFarmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

Flag Czech Republic
Digital Content Digital Content

Regadenoson Monohydrate

About the Company : Farmak, A.S. is a privately held chemical and pharmaceutical company based in the Czech Republic. It specializes in researching, developing and producing active pharmaceutical ingr...

Farmak, A.S. is a privately held chemical and pharmaceutical company based in the Czech Republic. It specializes in researching, developing and producing active pharmaceutical ingredients (APIs), intermediates and specialized chemicals. The company primarily focuses on exporting its products, with the main markets being the EU, USA, India, Japan and Latin America. Additionally, Farmak offers contract manufacturing and custom synthesis services through its R&D department to support the clients.
Farmak Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

Regadenoson Monohydrate

About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...

Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-approved API manufacturing facilities, a dedicated intermediate facility, and a R&D laboratory housing 400 scientists, Biophore has positioned itself as a global leader among API companies. It consistently ranks among the top 10 US DMF filers and has obtained over 150 patents worldwide in process and polymorph areas. Biophore's facilities have an impressive track record of successful audits by regulatory bodies such as USFDA, EMEA, ANVISA, COFEPRIS, and WHO GMP.
Biophore

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content

Regadenoson Monohydrate

About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...

Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout the entire API life cycle, from product development through sales. Transo-Pharm serves as a sourcing and regulatory marketing agent for API manufacturers. It aids clients in establishing DMFs and provides GMP consulting. With a dedicated regulatory department, a warehouse, proprietary IPs for API processes, and partnerships with laboratories, Transo-Pharm offers a wide range of services. It operates from its offices in Shanghai, Hong Kong, Singapore, and the US.
Transo Pharm USA Company Banner

04

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Regadenoson Monohydrate

About the Company : Anax Laboratories was established in 2012 as a custom synthesis laboratories specializing in synthesis of wide range of organic compounds to cater the needs of pharmaceutical and c...

Anax Laboratories was established in 2012 as a custom synthesis laboratories specializing in synthesis of wide range of organic compounds to cater the needs of pharmaceutical and chemical industries. Anax Laboratories is strategically located in hyderabad,the pharma capital of india , surrounded by high repute R&D institutes and companies. Anax Laboratories has cutting edge, modern organic synthesis and analytical lab to develop novel and established organic compounds. Anax Laboratories is guided by strong scientific advisory board from high repute R&D institutes like IICT, CCMB and also professors from universities in India and abroad.
blank

05

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Regadenoson Monohydrate

About the Company : BrightGene Bio-Medical Technology Co., Ltd. is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special gener...

BrightGene Bio-Medical Technology Co., Ltd. is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special generic APIs and FDFs with primary strategic focus on the regulated market. We have an exciting and very promising innovative pipeline including immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumor, novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastasis.
blank

06

Curia

U.S.A
Coatings Trends
Not Confirmed
arrow

Curia

U.S.A
arrow
Coatings Trends
Not Confirmed

Regadenoson Monohydrate

About the Company : Curia is a global contract research, development and manufacturing organization (CDMO), offering products and services across the drug development spectrum to help our partners tur...

Curia is a global contract research, development and manufacturing organization (CDMO), offering products and services across the drug development spectrum to help our partners turn their ideas into real-world impact. We partner closely with pharmaceutical and biotechnology companies to boost business performance and improve patients’ lives. From early discovery and development through manufacturing and commercialization, our suite of custom solutions allows us to tailor every engagement to your precise needs, whether that’s an independent project or an opportunity that cuts across the drug continuum.
blank

07

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Regadenoson

About the Company : A globally renowned manufacturer of Small Volume Parenterals (SVPs), Gland Pharma was founded in 1978 at Hyderabad by a visionary, PVN Raju, who has always thought far ahead of his...

A globally renowned manufacturer of Small Volume Parenterals (SVPs), Gland Pharma was founded in 1978 at Hyderabad by a visionary, PVN Raju, who has always thought far ahead of his time. Since inception, Gland Pharma stands testimony to the founder’s exemplary commitment to Quality, having emerged as a global player with presence in about 90 countries in five continents. We have a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions and ophthalmic solutions.
blank

08

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Regadenoson

About the Company : ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a w...

ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry.Combining cost-effective resources and productivity of Asia along with unmatched regulatory know-how, ScinoPharm is uniquely positioned to serve global pharmaceutical R&D and manufacturing needs at any level and for any company in this sector.
blank

09

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Regadenoson

About the Company : Sionc pharmaceuticals is specialized in manufacturing of complex and niche Active Pharmaceutical Ingredients in various therapeutic categories. Sionc has evolved as a reliable cont...

Sionc pharmaceuticals is specialized in manufacturing of complex and niche Active Pharmaceutical Ingredients in various therapeutic categories. Sionc has evolved as a reliable contributor in the generic drug industry for Regulatory markets with customer-centric approach since its inception in 2010. To Emerge as a Leading Global Pharmaceutical Company which creates value for all customers by offering excellence in product Quality Standard with committed service and be a significant contributor for global markets.
blank

10

Coatings Trends
Not Confirmed
arrow
arrow
Coatings Trends
Not Confirmed

Regadenoson

About the Company : SKVEN Technologies is a diverse pharmaceutical company that is committed to focusing on our customers while delivering consistently high performance. Our Vision, Mission and in Val...

SKVEN Technologies is a diverse pharmaceutical company that is committed to focusing on our customers while delivering consistently high performance. Our Vision, Mission and in Values provide the overall direction for our company, and provide us with the tools necessary to rise to any challenge by leveraging our collective hard work and effort along with our unwavering competitive spirit. SKVEN expertise and capabilities in pharmaceutical development and manufacturing will provide Customers with customized services and solutions for starting materials, intermediates, active ingredients and finished dosage form.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731263400,"product":"REGADENOSON STABDARD(QTY:500 MG)","address":"PLOT NO.C-24, MSN HOUSE, INDUSTRIAL","city":"HYDERABAD, AP","supplier":"MSN LIFE SCIENCES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ATHENS","customer":"DEMO SAPHARMACEUTICAL INDUSTRY","customerCountry":"GREECE","quantity":"0.00","actualQuantity":"0.5","unit":"GMS","unitRateFc":"75500","totalValueFC":"36801.2","currency":"USD","unitRateINR":6211169.8600000003,"date":"11-Nov-2024","totalValueINR":"3105584.93","totalValueInUsd":"36801.2","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"5508568","productDescription":"API","marketType":"REGULATED MARKET","country":"GREECE","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.C-24, MSN HOUSE, INDUSTRIAL, HYDERABAD, AP","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692210600,"product":"REGADENOSON ANHYDROUS T.NO: TL\/AZ\/23\/001944 BATCH NO: US22600799 4.19GRAM\/5000\/GRAM USD R&D","address":"SHIVARTH AMBIT,RAMDAS ROAD,,OFF SI NDHU BHAVAN ROAD, BODAKDEV","city":"AHMEDABAD","supplier":"CURIA GLOBAL INC","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"BAXTER PHARMACEUTICALS INDIA PRIVATE LTD","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"5000000","totalValueFC":"21100.9","currency":"USD","unitRateINR":"173043798.8","date":"17-Aug-2023","totalValueINR":"1747917.16","totalValueInUsd":"21100.9","indian_port":"AHEMDABAD AIR","hs_no":"29349990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"SHIVARTH AMBIT,RAMDAS ROAD,,OFF SI NDHU BHAVAN ROAD, BODAKDEV"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1702837800,"product":"REGADENOSON (QTY:123GMS, VALUE: USD 553500)","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"CURIA MISSOURI INC","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"DR REDDY'S LABORATORIES","customerCountry":"INDIA","quantity":"0.12","actualQuantity":"0.123","unit":"KGS","unitRateFc":"4500000","totalValueFC":"560527.2","currency":"USD","unitRateINR":"379350000","date":"18-Dec-2023","totalValueINR":"46660050","totalValueInUsd":"560527.2","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"9288765","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO O\\'HARE INT\\'L","supplierAddress":"2460 W BENNETT STREET SPRINGFIELD,MISSOURI 65807 USA United States United States United States United States","customerAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1707330600,"product":"REGADENOSON ANHYDROUS (QTY:100.01GMS, VALUE:USD 450045)","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"CURIA MISSOURI INC","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"DR REDDY'S LABORATORIES","customerCountry":"INDIA","quantity":"0.10","actualQuantity":"0.10001","unit":"KGS","unitRateFc":"4500000","totalValueFC":"455340","currency":"USD","unitRateINR":"377775000","date":"08-Feb-2024","totalValueINR":"37781277.75","totalValueInUsd":"455340","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"2049077","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO O\\'HARE INT\\'L","supplierAddress":"2460 W BENNETT STREET SPRINGFIELD,MISSOURI 65807 USA United States United States United States","customerAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1749407400,"product":"SST REGADENOSON MARKER SYSTEM SUITABILITY MARKER(LOT:REG-2-77)(QTY 250 MG @ 20 MG)SST REGADENOSON MARKER SYSTEM SUITABILITY MARKER(LOT:REG-2-7","address":"CLARIS CORPORATE HEAD QUARTERS,","city":"ELLISBRIDGE,AHMEDABD,GUJARAT,INDIA","supplier":"CURIA GLOBAL INC","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"BAXTER PHARMACEUTICALS INDIA PRIVATE LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.25","unit":"GMS","unitRateFc":"28000","totalValueFC":"7067.2","currency":"USD","unitRateINR":"2429000","date":"09-Jun-2025","totalValueINR":"607250","totalValueInUsd":"7067.2","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"2555233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO O\\'HARE INT\\'L","supplierAddress":"26 CORPORATE CIRCLE ALBANY NY,N Y 12203 United States America SDNF United States America","customerAddress":"CLARIS CORPORATE HEAD QUARTERS,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1750098600,"product":"REGADENOSON ANHYDROUS (LOT:US24600090) REGADENOSON ANHYDROUS (LOT:US24600090)","address":"CLARIS CORPORATE HEAD QUARTERS,","city":"ELLISBRIDGE,AHMEDABD,GUJARAT,INDIA","supplier":"CURIA GLOBAL INC","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"BAXTER PHARMACEUTICALS INDIA PRIVATE LTD","customerCountry":"INDIA","quantity":"0.05","actualQuantity":"53.1","unit":"GMS","unitRateFc":"5000","totalValueFC":"268047.9","currency":"USD","unitRateINR":"433750","date":"17-Jun-2025","totalValueINR":"23032125","totalValueInUsd":"268047.9","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"2712836","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO O\\'HARE INT\\'L","supplierAddress":"26 CORPORATE CIRCLE ALBANY NY,N Y 12203 United States America SDNF United States America","customerAddress":"CLARIS CORPORATE HEAD QUARTERS,"}]
17-Aug-2023
17-Jun-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 313348-27-5 / Regadenoson Monohydrate API manufacturers, exporters & distributors?

Regadenoson Monohydrate manufacturers, exporters & distributors 1

64

PharmaCompass offers a list of Regadenoson Monohydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Regadenoson Monohydrate manufacturer or Regadenoson Monohydrate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Regadenoson Monohydrate manufacturer or Regadenoson Monohydrate supplier.

PharmaCompass also assists you with knowing the Regadenoson Monohydrate API Price utilized in the formulation of products. Regadenoson Monohydrate API Price is not always fixed or binding as the Regadenoson Monohydrate Price is obtained through a variety of data sources. The Regadenoson Monohydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Regadenoson Monohydrate

Synonyms

313348-27-5, Lexiscan, Rapiscan, Cvt-3146, Regadenoson anhydrous, 2-[4-[(methylamino)carbonyl]-1h-pyrazol-1-yl]adenosine

Cas Number

313348-27-5

Unique Ingredient Identifier (UNII)

7AXV542LZ4

About Regadenoson Monohydrate

Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

Regadenoson Manufacturers

A Regadenoson manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Regadenoson, including repackagers and relabelers. The FDA regulates Regadenoson manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Regadenoson API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Regadenoson manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Regadenoson Suppliers

A Regadenoson supplier is an individual or a company that provides Regadenoson active pharmaceutical ingredient (API) or Regadenoson finished formulations upon request. The Regadenoson suppliers may include Regadenoson API manufacturers, exporters, distributors and traders.

click here to find a list of Regadenoson suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Regadenoson USDMF

A Regadenoson DMF (Drug Master File) is a document detailing the whole manufacturing process of Regadenoson active pharmaceutical ingredient (API) in detail. Different forms of Regadenoson DMFs exist exist since differing nations have different regulations, such as Regadenoson USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Regadenoson DMF submitted to regulatory agencies in the US is known as a USDMF. Regadenoson USDMF includes data on Regadenoson's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Regadenoson USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Regadenoson suppliers with USDMF on PharmaCompass.

Regadenoson WC

A Regadenoson written confirmation (Regadenoson WC) is an official document issued by a regulatory agency to a Regadenoson manufacturer, verifying that the manufacturing facility of a Regadenoson active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Regadenoson APIs or Regadenoson finished pharmaceutical products to another nation, regulatory agencies frequently require a Regadenoson WC (written confirmation) as part of the regulatory process.

click here to find a list of Regadenoson suppliers with Written Confirmation (WC) on PharmaCompass.

Regadenoson NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Regadenoson as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Regadenoson API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Regadenoson as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Regadenoson and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Regadenoson NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Regadenoson suppliers with NDC on PharmaCompass.

Regadenoson GMP

Regadenoson Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Regadenoson GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Regadenoson GMP manufacturer or Regadenoson GMP API supplier for your needs.

Regadenoson CoA

A Regadenoson CoA (Certificate of Analysis) is a formal document that attests to Regadenoson's compliance with Regadenoson specifications and serves as a tool for batch-level quality control.

Regadenoson CoA mostly includes findings from lab analyses of a specific batch. For each Regadenoson CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Regadenoson may be tested according to a variety of international standards, such as European Pharmacopoeia (Regadenoson EP), Regadenoson JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Regadenoson USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty